Can Sectra (OM:SECT B) Justify Its Valuation On Its Brazil Cloud Hospital Push?

Sectra enters Brazil with cloud-focused hospital push

Sectra (OM:SECT B) has agreed a partnership with S&S Partners to enter Brazil, Latin America's largest healthcare market. The companies will center their early efforts on the Sectra One Cloud imaging platform for hospital clients.

Sectra's latest Brazil move lands at a time when momentum has been building in the share price, with a 1-day share price return of 2.33%, a year-to-date share price return of 24.79% and a three-year total shareholder return of 136.38%, even though the one-year total shareholder return has edged down 1.19%.

Look beyond Sectra and this Brazil push by checking which hospital IT and healthcare imaging specialists are already moving on 125 healthcare AI stocks.

Bulls point to Sectra’s Brazil entry and long run momentum in shareholder returns. Bears flag a zero value score and an intrinsic value that screens rich. Which side does the current valuation math support?

Most Popular Narrative: 12% Undervalued

Sectra last closed at SEK299, while the most followed narrative pegs fair value around SEK340. The Brazil launch now sits against a view that the shares trade below that reference point even with a rich valuation profile.

Transition to an as-a-service model is expected to enhance future revenue stability and growth, with a significant increase in recurring cloud revenue anticipated as products move from hardware-based to cloud solutions. This transition is likely to impact revenue positively in the long term.

See why 4 investors see Sectra as 12% undervalued.

Sectra’s fair value estimate of SEK340 is built off those revenue and margin assumptions using a 6.2% discount rate. Investors are effectively weighing a forecast move to higher recurring income against a current valuation that already prices in strong profitability. The result leaves a clear gap between the SEK299 share price and that SEK340 marker, while still flagging that the business scores zero on value checks and trades at a premium to many Healthcare Services peers. Result: Fair Value of SEK340 (UNDERVALUED)

Still, Sectra’s heavy reliance on large contracts and the profit hit that can come from shifting away from upfront licenses both leave that upbeat narrative exposed.

Find out about the key risks to this Sectra narrative.

Another View on Sectra’s valuation

The story flips once the focus shifts from that SEK340 fair value to what the current P/E implies. Sectra trades on about 93x earnings, compared with 28.9x for the global Healthcare Services group and a fair ratio estimate of 36.6x. That is a wide gap. Is the extra multiple really justified by future growth, or is it stretching the margin of safety?

For a closer look at how earnings, pricing and the fair ratio fit together, take a few minutes with See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Mixed signals or clear opportunity: you do not need to take anyone’s word for it. Run the numbers yourself, weigh the Brazil story, then see what the current optimism is based on through 2 key rewards.

Looking for more Sectra-sized investment ideas?

If Sectra has your attention, do not stop at a single ticker. Broader context often comes from scanning other opportunities before deciding where fresh capital goes.

• Spot potential bargains early by reviewing companies that screen as high quality yet priced below their estimated worth through 179 high quality undervalued stocks.
• Strengthen your income stream by focusing on businesses that pair resilience with payout potential using the 226 dividend fortresses.
• Sleep easier at night by filtering for companies that carry sturdier balance sheets and fundamentals through the list of solid balance sheet and fundamentals (206 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com